Advancing IgAN Care: Exploring the Next Wave of Treatments

Panelists discuss how IgA nephropathy presents in patients, often remaining asymptomatic until significant progression occurs, and explore the various subtypes that exhibit distinct clinical features.

Panelists discuss the progressive nature of immunoglobulin AIgA nephropathy (IgAN) and identify key factors that may accelerate its progression toward end-stage renal disease (ESRD).

Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.

Panelists discuss potential biomarkers and clinical indicators that can aid in predicting disease outcomes for individual patients with IgA nephropathy.

Panelists discuss the importance of screening and monitoring family members of individuals with IgA nephropathy, noting that up to 15% of cases are familial and outlining recommendations for the frequency of such assessments.

Panelists discuss how IgA nephropathy affects patients’ quality of life, addressing both the physical symptoms and the emotional challenges associated with the condition.